JP2017507320A - 前立腺癌分類 - Google Patents

前立腺癌分類 Download PDF

Info

Publication number
JP2017507320A
JP2017507320A JP2016538689A JP2016538689A JP2017507320A JP 2017507320 A JP2017507320 A JP 2017507320A JP 2016538689 A JP2016538689 A JP 2016538689A JP 2016538689 A JP2016538689 A JP 2016538689A JP 2017507320 A JP2017507320 A JP 2017507320A
Authority
JP
Japan
Prior art keywords
prostate cancer
subject
expression level
srsf5
pdk4
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2016538689A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017507320A5 (enExample
Inventor
スティーブン・ウォーカー
アンドリーナ・マッキャビガン
ティモシー・デイビソン
リチャード・ケネディ
ポール・ハーキン
ローラ・ヒル
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Almac Diagnostics Ltd
Original Assignee
Almac Diagnostics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Almac Diagnostics Ltd filed Critical Almac Diagnostics Ltd
Publication of JP2017507320A publication Critical patent/JP2017507320A/ja
Publication of JP2017507320A5 publication Critical patent/JP2017507320A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • G01N33/57555—
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/60—Complex ways of combining multiple protein biomarkers for diagnosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • General Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
JP2016538689A 2013-12-12 2014-12-12 前立腺癌分類 Pending JP2017507320A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1322034.8 2013-12-12
GBGB1322034.8A GB201322034D0 (en) 2013-12-12 2013-12-12 Prostate cancer classification
PCT/GB2014/053694 WO2015087088A2 (en) 2013-12-12 2014-12-12 Prostate cancer classification

Publications (2)

Publication Number Publication Date
JP2017507320A true JP2017507320A (ja) 2017-03-16
JP2017507320A5 JP2017507320A5 (enExample) 2018-01-25

Family

ID=50030858

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016538689A Pending JP2017507320A (ja) 2013-12-12 2014-12-12 前立腺癌分類

Country Status (13)

Country Link
US (1) US10196697B2 (enExample)
EP (1) EP3080293B1 (enExample)
JP (1) JP2017507320A (enExample)
KR (1) KR20160098351A (enExample)
CN (1) CN105940117A (enExample)
AU (1) AU2014363173A1 (enExample)
BR (1) BR112016013182A2 (enExample)
CA (1) CA2932553A1 (enExample)
GB (1) GB201322034D0 (enExample)
IL (1) IL246067A0 (enExample)
MX (1) MX2016007333A (enExample)
SG (1) SG11201604508PA (enExample)
WO (1) WO2015087088A2 (enExample)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022059105A (ja) * 2020-09-30 2022-04-13 国立大学法人大阪大学 癌に関連する新規バイオマーカー
JP2023538783A (ja) * 2020-08-31 2023-09-11 コーニンクレッカ フィリップス エヌ ヴェ 前立腺がんの放射線治療用線量の選択
JP2023538944A (ja) * 2020-08-31 2023-09-12 コーニンクレッカ フィリップス エヌ ヴェ 前立腺がん対象者の治療に対する応答の予測又は前立腺がん対象者の治療の個人化
JP2023538868A (ja) * 2020-08-31 2023-09-12 コーニンクレッカ フィリップス エヌ ヴェ Ｐｄｅ４ｄ７相関遺伝子に基づく放射線療法に対する前立腺癌被験者の反応の予測

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11035005B2 (en) 2012-08-16 2021-06-15 Decipher Biosciences, Inc. Cancer diagnostics using biomarkers
CA2996426A1 (en) * 2015-10-05 2017-04-13 Cedars-Sinai Medical Center Method of classifying and diagnosing cancer
US20190024184A1 (en) * 2015-12-23 2019-01-24 Fred Hutchinson Cancer Research Center Distinguishing metastatic-lethal prostate cancer from indolent prostate cancer using methylation status of epigenetic markers
CA3011106A1 (en) * 2016-01-20 2017-07-27 Dana-Farber Cancer Institute, Inc. Compositions and methods for screening and identifying clinically aggressive prostate cancer
WO2018039490A1 (en) 2016-08-24 2018-03-01 Genomedx Biosciences, Inc. Use of genomic signatures to predict responsiveness of patients with prostate cancer to post-operative radiation therapy
EP3593140A4 (en) * 2017-03-09 2021-01-06 Decipher Biosciences, Inc. SUBTYPING PROSTATE CANCER TO PREDICT RESPONSE TO HORMONE THERAPY
US12497660B2 (en) 2017-08-04 2025-12-16 Veracyte SD, Inc. Use of immune cell-specific gene expression for prognosis of prostate cancer and prediction of responsiveness to radiation therapy
WO2019195658A1 (en) * 2018-04-05 2019-10-10 Dana-Farber Cancer Institute, Inc. Sting levels as a biomarker for cancer immunotherapy
CN109295208A (zh) * 2018-10-26 2019-02-01 德阳市人民医院 Pi15作为骨关节炎标志物的应用
AU2020215177A1 (en) * 2019-01-30 2021-08-12 Janssen Pharmaceutica Nv Methods of treating prostate cancer based on molecular subtypes
GB201917428D0 (en) * 2019-11-29 2020-01-15 Univ Newcastle Prostate cancer diagnostic
CN111518908B (zh) * 2020-05-18 2023-10-17 奥尔文泰生物科技(杭州)有限公司 尿液前列腺癌标志物组合及其在制备精准诊断试剂中的用途
CN113234820A (zh) * 2021-04-29 2021-08-10 北京艾克伦医疗科技有限公司 鉴定前列腺癌状态的方法和试剂盒
WO2023135485A1 (en) * 2022-01-13 2023-07-20 Oslo Universitetssykehus Hf Prostate cancer markers and uses thereof
EP4253567A1 (en) 2022-03-31 2023-10-04 OncoAssure Limited A method of predicting risk of an aggressive or recurrent cancer
WO2023220314A1 (en) * 2022-05-12 2023-11-16 Veracyte SD, Inc. Prognosis and treatment of molecular subtypes of prostate cancer
CN116891523B (zh) * 2023-05-24 2024-05-17 深圳晶蛋生物医药科技有限公司 一种trpm3截短体、包含其的细胞系及其用途

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007525220A (ja) * 2004-02-27 2007-09-06 オンコセラピー・サイエンス株式会社 Ｐｉｎ−ｐｒｃ移行遺伝子
JP2008271979A (ja) * 2000-11-28 2008-11-13 Wyeth 前立腺癌の診断および治療に有用なｆｋｂｐ核酸およびポリペプチドの発現分析
JP2010529955A (ja) * 2007-05-30 2010-09-02 エフ．ホフマン−ラ ロシュ アーゲー 癌細胞傷害性を介在するキメラ及びヒト化抗−ｃｄ４４抗体
JP2012529021A (ja) * 2009-06-04 2012-11-15 メタノミクス ヘルス ゲーエムベーハー 前立腺癌を診断する手段と方法

Family Cites Families (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2774121B2 (ja) 1987-07-31 1998-07-09 ザ ボード オブ トラスティーズ オブ ザ リーランド スタンフォード ジュニア ユニバーシティ 標的ポリヌクレオチド配列の選択的増幅
ZA899593B (en) 1988-12-16 1990-09-26 Siska Diagnostics Inc Self-sustained,sequence replication system
US5437975A (en) 1991-02-25 1995-08-01 California Institute Of Biological Research Consensus sequence primed polymerase chain reaction method for fingerprinting genomes
US6017704A (en) 1996-06-03 2000-01-25 The Johns Hopkins University School Of Medicine Method of detection of methylated nucleic acid using agents which modify unmethylated cytosine and distinguishing modified methylated and non-methylated nucleic acids
US7220557B2 (en) 1997-04-24 2007-05-22 Human Genome Sciences, Inc. METH1 polynucleotides
AU2002214576A1 (en) 2000-10-13 2002-04-22 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Genes related to development of refractory prostate cancer
WO2003009814A2 (en) 2001-07-25 2003-02-06 Millennium Pharmaceuticals, Inc. Novel genes, compositions, kits, and methods for identification, assessment, prevention, and therapy of prostate cancer
US7229774B2 (en) 2001-08-02 2007-06-12 Regents Of The University Of Michigan Expression profile of prostate cancer
US20040029151A1 (en) 2002-04-09 2004-02-12 Affymetrix, Inc. Molecular genetic profiling of gleason grades 3 and 4/5 prostate cancer
US20050032065A1 (en) 2002-06-24 2005-02-10 Afar Daniel E. H. Methods of prognosis of prostate cancer
EP1382969A1 (en) 2002-07-17 2004-01-21 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Diagnosis and prevention of cancer cell invasion
US20050259483A1 (en) 2002-09-30 2005-11-24 Oncotherapy Science, Inc. Genes and polypeptides relating to prostate cancers
WO2004067726A2 (en) 2003-01-29 2004-08-12 Keck Graduate Institute Isothermal reactions for the amplification of oligonucleotides
US20040223970A1 (en) 2003-02-28 2004-11-11 Daniel Afar Antibodies against SLC15A2 and uses thereof
US20070048738A1 (en) 2003-07-14 2007-03-01 Mayo Foundation For Medical Education And Research Methods and compositions for diagnosis, staging and prognosis of prostate cancer
US7666595B2 (en) * 2005-02-25 2010-02-23 The Brigham And Women's Hospital, Inc. Biomarkers for predicting prostate cancer progression
WO2006110264A2 (en) 2005-03-16 2006-10-19 Sidney Kimmel Cancer Center Methods and compositions for predicting death from cancer and prostate cancer survival using gene expression signatures
WO2006113529A2 (en) 2005-04-15 2006-10-26 Becton, Dickinson And Company Diagnosis of sepsis
EP1717320A1 (en) 2005-04-26 2006-11-02 TopoTarget Germany AG Identification of human gene sequences of cancer antigens expressed in metastatic carcinoma and involved in metastasis formation, and their use in cancer diagnosis, prognosis and therapy
WO2007030919A1 (en) 2005-09-14 2007-03-22 National Research Council Of Canada Molecular method for diagnosis of prostate cancer
US20070059753A1 (en) 2005-09-15 2007-03-15 Tatiana Vener Detecting gene methylation
CA2629008A1 (en) 2005-11-08 2007-09-13 Euclid Diagnostics Llc Materials and methods for assaying for methylation of cpg islands associated with genes in the evaluation of cancer
WO2008067065A2 (en) 2006-10-19 2008-06-05 Shiv Srivastava Methods, kits, and systems for diagnosing and prognosing prostate cancer using secreted biomarkers
US8338109B2 (en) 2006-11-02 2012-12-25 Mayo Foundation For Medical Education And Research Predicting cancer outcome
WO2008086478A2 (en) 2007-01-10 2008-07-17 Henry Ford Health System Methods and compositions for identification of prostate cancer markers
AU2007350331A1 (en) 2007-03-30 2008-10-09 Source Precision Medicine, Inc. D/B/A Source Mdx Gene expression profiling for identification, monitoring, and treatment of prostate cancer
EP2190478B1 (en) 2007-08-24 2016-03-23 Oncotherapy Science, Inc. Dkk1 oncogene as therapeutic target for cancer and a diagnosing marker
WO2009151503A2 (en) 2008-04-10 2009-12-17 University Of Florida Research Foundation, Inc. Compositions and methods for the treatment of a neoplasia
US20110159498A1 (en) 2008-04-11 2011-06-30 China Synthetic Rubber Corporation Methods, agents and kits for the detection of cancer
US20110136683A1 (en) 2008-05-28 2011-06-09 Genomedx Biosciences, Inc. Systems and Methods for Expression-Based Discrimination of Distinct Clinical Disease States in Prostate Cancer
US20090298082A1 (en) 2008-05-30 2009-12-03 Klee George G Biomarker panels for predicting prostate cancer outcomes
US20120009581A1 (en) 2008-07-08 2012-01-12 Bankaitis-Davis Danute M Gene Expression Profiling for Predicting the Survivability of Prostate Cancer Subjects
CN102159727A (zh) 2008-07-16 2011-08-17 达纳-法伯癌症研究院有限公司 与前列腺癌有关的信号和胆碱磷酸决定子以及它们的使用方法
US20100055705A1 (en) 2008-08-29 2010-03-04 Wilson Gerald M Compositions and methods for diagnosing and treating cancer
CA2742324A1 (en) 2008-10-30 2010-06-03 Caris Life Sciences Luxembourg Holdings, S.A.R.L. Methods for assessing rna patterns
EP2370813A4 (en) 2008-12-04 2012-05-23 Univ California MATERIALS AND METHODS FOR DIAGNOSIS AND PRESENTATION OF PROSTATE CANCER
US20120041274A1 (en) 2010-01-07 2012-02-16 Myriad Genetics, Incorporated Cancer biomarkers
CN102439176B (zh) 2009-05-12 2018-11-23 皇家飞利浦电子股份有限公司 用作恶性的、激素-敏感的前列腺癌的标志物的磷酸二酯酶4d7
JP6148007B2 (ja) 2009-05-12 2017-06-14 コーニンクレッカ フィリップス エヌ ヴェＫｏｎｉｎｋｌｉｊｋｅ Ｐｈｉｌｉｐｓ Ｎ．Ｖ． 前立腺癌マーカーとしてのホスホジエステラーゼ４ｄ７
US8993604B2 (en) 2009-06-30 2015-03-31 Siga Technologies, Inc. Treatment and prevention of dengue virus infections
EP2309273B1 (en) 2009-09-16 2016-05-18 ZEILLINGER, Robert Novel tumor marker determination
EP2692871A1 (en) 2009-12-01 2014-02-05 Compendia Bioscience, Inc. Classification of cancers
WO2011094233A1 (en) 2010-01-26 2011-08-04 The Johns Hopkins University Methods of disease classification or prognosis for prostate cancer based on expression of cancer/testis antigens
WO2011106709A2 (en) 2010-02-26 2011-09-01 Board Of Regents, The University Of Texas System Epithelial biomarkers for cancer prognosis
BR112012022641A2 (pt) 2010-03-11 2017-02-14 Oncotherapy Science Inc peptídeos hjurp e vacinas que incluem os mesmos
WO2011153287A2 (en) 2010-06-01 2011-12-08 Indiana University Research And Technology Corporation Materials and methods for diagnosing and predicting the course of prostate cancer
CA2804391A1 (en) 2010-07-07 2012-01-12 Myriad Genetics, Inc. Gene signatures for cancer prognosis
WO2012018609A2 (en) 2010-07-26 2012-02-09 The Johns Hopkins University Mig6 and therapeutic efficacy
ES2925983T3 (es) 2010-07-27 2022-10-20 Genomic Health Inc Método para usar la expresión génica para determinar el pronóstico del cáncer de próstata
WO2012030840A2 (en) 2010-08-30 2012-03-08 Myriad Genetics, Inc. Gene signatures for cancer diagnosis and prognosis
EP2702177B1 (en) 2011-04-28 2017-04-12 New York University Genomic signatures of metastasis in prostate cancer
AU2012275500A1 (en) 2011-06-27 2014-01-16 Dana-Farber Cancer Institute, Inc. Signatures and determinants associated with prostate cancer progression and methods of use thereof
US20130079241A1 (en) * 2011-09-15 2013-03-28 Jianhua Luo Methods for Diagnosing Prostate Cancer and Predicting Prostate Cancer Relapse
GB201206209D0 (en) 2012-04-06 2012-05-23 Univ Leuven Kath Marker gene based diagnosis, staging and prognosis of prostate caner
ES2673960T3 (es) 2011-12-22 2018-06-26 Ionis Pharmaceuticals, Inc. Métodos para modular la expresión de un transcrito-1 de adenocarcinoma en pulmón asociado a metástasis (MALAT-1)
DK3179393T3 (da) 2012-01-31 2020-07-27 Genomic Health Inc Genexpressionsprofilalgoritme og -test til bestemmelse af prognosen for prostatakræft
TW201343920A (zh) 2012-03-29 2013-11-01 財團法人國家衛生研究院 預測前列腺癌預後之分子標記、方法與套組
BR102012007246A2 (pt) 2012-03-30 2016-02-10 Fundação Antonio Prudente métodos para prognóstico e classificação de resultados de um evento
US20130288967A1 (en) 2012-04-25 2013-10-31 Euclid Diagnostics Llc Materials and methods for cancer diagnosis by evaluation of the methylation status of cpg islands on chromosomes 6 and 8
CN103146688B (zh) 2012-09-12 2015-05-13 上海长海医院 长链非编码rna作为疾病诊断血液分子标志物的应用

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008271979A (ja) * 2000-11-28 2008-11-13 Wyeth 前立腺癌の診断および治療に有用なｆｋｂｐ核酸およびポリペプチドの発現分析
JP2007525220A (ja) * 2004-02-27 2007-09-06 オンコセラピー・サイエンス株式会社 Ｐｉｎ−ｐｒｃ移行遺伝子
JP2010529955A (ja) * 2007-05-30 2010-09-02 エフ．ホフマン−ラ ロシュ アーゲー 癌細胞傷害性を介在するキメラ及びヒト化抗−ｃｄ４４抗体
JP2012529021A (ja) * 2009-06-04 2012-11-15 メタノミクス ヘルス ゲーエムベーハー 前立腺癌を診断する手段と方法

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
S.KAMARAJUGADDA、他６名: "Glucose Oxidation Modulates Anoikis and Tumor Metastasis", MOLECULAR AND CELLULAR BIOLOGY, vol. 32, no. 10, JPN6018038451, May 2012 (2012-05-01), pages 1893 - 1907, ISSN: 0004191686 *

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023538783A (ja) * 2020-08-31 2023-09-11 コーニンクレッカ フィリップス エヌ ヴェ 前立腺がんの放射線治療用線量の選択
JP2023538944A (ja) * 2020-08-31 2023-09-12 コーニンクレッカ フィリップス エヌ ヴェ 前立腺がん対象者の治療に対する応答の予測又は前立腺がん対象者の治療の個人化
JP2023538868A (ja) * 2020-08-31 2023-09-12 コーニンクレッカ フィリップス エヌ ヴェ Ｐｄｅ４ｄ７相関遺伝子に基づく放射線療法に対する前立腺癌被験者の反応の予測
JP7790427B2 (ja) 2020-08-31 2025-12-23 コーニンクレッカ フィリップス エヌ ヴェ 前立腺がん対象者の治療に対する応答の予測又は前立腺がん対象者の治療の個人化
JP2022059105A (ja) * 2020-09-30 2022-04-13 国立大学法人大阪大学 癌に関連する新規バイオマーカー
JP7477872B2 (ja) 2020-09-30 2024-05-07 国立大学法人大阪大学 癌に関連する新規バイオマーカー

Also Published As

Publication number Publication date
US20160312294A1 (en) 2016-10-27
EP3080293A2 (en) 2016-10-19
CA2932553A1 (en) 2015-06-18
KR20160098351A (ko) 2016-08-18
US10196697B2 (en) 2019-02-05
CN105940117A (zh) 2016-09-14
MX2016007333A (es) 2016-10-13
GB201322034D0 (en) 2014-01-29
WO2015087088A2 (en) 2015-06-18
AU2014363173A1 (en) 2016-07-07
IL246067A0 (en) 2016-07-31
SG11201604508PA (en) 2016-07-28
WO2015087088A3 (en) 2015-09-17
BR112016013182A2 (pt) 2017-09-26
EP3080293B1 (en) 2019-03-13

Similar Documents

Publication Publication Date Title
EP3080293B1 (en) Prostate cancer classification
Zheng et al. Leptin receptor maintains cancer stem-like properties in triple negative breast cancer cells
Wouters et al. Comprehensive DNA methylation study identifies novel progression-related and prognostic markers for cutaneous melanoma
Payne et al. DNA methylation biomarkers of prostate cancer: Confirmation of candidates and evidence urine is the most sensitive body fluid for non‐invasive detection
Zhang et al. Downregulation of long non-coding RNA HCG11 predicts a poor prognosis in prostate cancer
EP3310927B1 (en) Gene signatures predictive of metastatic disease
Liu et al. Diagnostic role of Wnt pathway gene promoter methylation in non small cell lung cancer
US20160273048A1 (en) Methods for the surveillance, diagnosis and screening of bladder cancer
EP3194621B1 (en) A method of predicting risk of recurrence of cancer
WO2015073949A1 (en) Method of subtyping high-grade bladder cancer and uses thereof
Yang et al. Systematic screening of protein-coding gene expression identified HMMR as a potential independent indicator of unfavorable survival in patients with papillary muscle-invasive bladder cancer
WO2012125411A1 (en) Methods of predicting prognosis in cancer
Zhang et al. ZNF154 is a promising diagnosis biomarker and predicts biochemical recurrence in prostate cancer
Amato et al. RASSF1 tumor suppressor gene in pancreatic ductal adenocarcinoma: correlation of expression, chromosomal status and epigenetic changes
US20160010157A1 (en) Methods and compositions relating to proliferative disorders of the prostate
WO2009074364A1 (en) Novel prognostic breast cancer marker
Liu et al. DNA hypermethylation of MAL gene may act as an independent predictor of favorable prognosis in patients with colorectal cancer
Moğul et al. The PD-L1 Promoter Methylation Predicts Gene And Protein Expression Levels in Urothelial Carcinoma
Chehade et al. Clinical implications of liquid biopsies in urogenital tumors: a narrative review
Wang et al. Effect of upregulation of DD3 on early detection and prognosis in prostate cancer
US12545961B2 (en) Method of predicting risk of recurrence of cancer
Snyder et al. Discovery and Validation of Clinically Relevant Long Non-Coding RNAs in Colorectal Cancer. Cancers 2022, 14, 3866
Dakubo Prostate Cancer Biomarkers in Circulation
Petricca Non-Invasive Detection and Classification of Prostate Cancer Using Plasma Cell-Free DNA Methylomes
McNeil et al. Molecular signatures of bladder cancer

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20171211

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20171211

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20180906

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20181002

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20181221

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20190521

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190809

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20200114

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20200804